The Sirtuin family: therapeutic targets to treat diseases of aging.
Sirtuins have emerged as therapeutic targets to treat age-related diseases. There are seven human Sirtuins (SIRT1-7) that display diversity in cellular localization and function. Growing evidence suggests that small-molecule activators of SIRT1 may counteract age-related afflictions such as type 2 diabetes. Alternatively, inhibitors of SIRT2 may be useful in the treatment of neurodegenerative diseases such as Parkinson's disease. Recent discoveries of small-molecule and protein modulators of Sirtuin deacetylation activity have provided enormous insight into the biological and molecular functions of Sirtuins and have validated their potential as therapeutics.
Milne
Jill C
JC
Sirtris Pharmaceuticals, Inc., 790 Memorial Drive, Cambridge, MA 02139, USA. jmilne@sirtrispharma.com
Denu
John M
JM
D000375:Aging / Q000473:pathology*; D015195:Drug Design; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D005853:Geriatrics; D006801:Humans; D037761:Sirtuins / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004791:Enzyme Inhibitors; D037761:Sirtuins